Patient safety and compliance in aesthetic pharmacy: theoretical foundations and an auditable conceptual model for screening, patient education, documentation and monitoring of adverse events

Patient safety and compliance in aesthetic pharmacy: theoretical foundations and an auditable conceptual model for screening, patient education, documentation and monitoring of adverse events

Authors

  • Monique Silva Mello Author

DOI:

https://doi.org/10.51473/rcmos.v1i1.2026.2221

Keywords:

Aesthetic Pharmacy; patient safety; quality management; risk management; cosmetovigilance; traceability; patient education.

Abstract

The expansion of products and services associated with Aesthetic Pharmacy intensifies the need for conceptual frameworks capable of supporting patient safety, quality and compliance in ambulatory and community care settings. Although cosmetics and personal hygiene products are mostly for external use, undesirable effects and technical complaints may occur and require post-use surveillance mechanisms. In Brazil, cosmetovigilance is defined as a set of activities that includes identification, notification, evaluation, investigation, monitoring, communication and prevention of adverse reactions arising from the normal or reasonably predictable use of cosmetic products, also covering events related to ineffectiveness, misuse and technical complaints that result in damage. At the same time, classic quality and safety references (structure–process–result; systemic error approaches) offer a basis for discussing why screening, patient education, document traceability and continuous improvement should be treated as safety “infrastructure” and not as accessory requirements. This article, of a conceptual/theoretical nature, integrates national and international literature and proposes an auditable implementation model for Aesthetic Pharmacy organized into six pillars: governance and responsibilities; risk screening and stratification; patient education and risk communication; documentation and traceability; adverse event surveillance (including cosmetovigilance when applicable); and continuous improvement. A maturity model in levels, frequent barriers (time, operational variability, training gaps, commercial pressure and underreporting) and mitigation strategies are also discussed. It is concluded that the consolidation of safety in Aesthetic Pharmacy depends less on specific actions and more on the institutionalization of processes, sufficient minimum records and risk-oriented organizational learning. 

Downloads

Download data is not yet available.

References

DONABEDIAN, A. The quality of care: how can it be assessed? JAMA, v. 260, n. 12, p. 1743–1748, 1988.

REASON, J. Human error: models and management. BMJ, v. 320, n. 7237, p. 768–770, 2000.

KOHN, L. T.; CORRIGAN, J. M.; DONALDSON, M. S. (ed.). To err is human: building a safer health system. Washington, DC: National Academies Press, 2000.

ORGANIZAÇÃO MUNDIAL DA SAÚDE. Global patient safety action plan 2021–2030. 2021.

INTERNATIONAL ORGANIZATION FOR STANDARDIZATION. ISO 9001:2015 — quality management systems — requirements. Geneva: ISO, 2015.

INTERNATIONAL ORGANIZATION FOR STANDARDIZATION. ISO 31000:2018 — risk management — guidelines. Geneva: ISO, 2018.

INSTITUTE FOR HEALTHCARE IMPROVEMENT. Model for improvement.

AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Manual de inspeção das boas práticas de cosmetovigilância. Brasília: Anvisa, 2025.

AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Notificações — cosméticos (eventos adversos e queixas técnicas).

AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Nova norma torna obrigatório notificar eventos adversos graves com cosméticos. 2025.

COMISSÃO EUROPEIA. SUE reporting guidelines. 2013.

UNITED STATES. FOOD AND DRUG ADMINISTRATION. FDA issues updated instructions for serious adverse event reporting for cosmetic products. 2023.

UNITED STATES. FOOD AND DRUG ADMINISTRATION. Modernization of cosmetics regulation act of 2022 (MoCRA). 2026.

UNITED STATES. FOOD AND DRUG ADMINISTRATION. How to report a cosmetic product related complaint. 2026.

TOKLU, H. Z. et al. Cosmetovigilance: a review of the current literature. Journal of Family Medicine and Primary Care, v. 8, n. 5, p. 1540–1545, 2019.

ALTIOKKA, İ.; ÜNER, M. Safety in cosmetics and cosmetovigilance, current regulations in Türkiye. Turkish Journal of Pharmaceutical Sciences, v. 19, n. 5, p. 610–617, 2022.

TEIXEIRA, A. P. C. P. et al. Análise descritiva das notificações de eventos adversos de produtos cosméticos registradas no Notivisa, no período de 2006 a 2018. Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia, v. 7, n. 4, p. 17–25, 2019.

RENNER, G. et al. Cosmetics Europe guidelines on the management of undesirable effects and reporting of serious undesirable effects from cosmetics in the European Union. Cosmetics, v. 4, n. 1, 2017.

Published

2026-04-09

How to Cite

MELLO , Monique Silva. Patient safety and compliance in aesthetic pharmacy: theoretical foundations and an auditable conceptual model for screening, patient education, documentation and monitoring of adverse events: Patient safety and compliance in aesthetic pharmacy: theoretical foundations and an auditable conceptual model for screening, patient education, documentation and monitoring of adverse events. Multidisciplinary Scientific Journal The Knowledge, Brasil, v. 1, n. 1, 2026. DOI: 10.51473/rcmos.v1i1.2026.2221. Disponível em: https://submissoesrevistarcmos.com.br/rcmos/article/view/2221. Acesso em: 10 apr. 2026.